Occurrence of Graves' disease during retreatment with interferon-alpha 2a for chronic hepatitis C

Intern Med. 1995 Nov;34(11):1097-1100. doi: 10.2169/internalmedicine.34.1097.

Abstract

The present report describes a patient who developed Graves' disease 3 months after inception of retreatment with higher doses of interferon-alpha 2a for chronic hepatitis C, although the initial 6-month treatment caused no serious adverse reactions. Severe hyperthyroidism continued despite discontinuation of interferon-alpha 2a, and the patient was subsequently treated with 131I. This case suggests careful evaluation of the safety of retreatment to prevent manifestation of such a complication in the retreatment of chronic hepatitis C with interferon.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Chronic Disease
  • Female
  • Graves Disease / etiology*
  • Graves Disease / metabolism
  • Hepatitis C / complications
  • Hepatitis C / metabolism
  • Hepatitis C / therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Recombinant Proteins
  • Recurrence

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins